1.Exploration of an Efficient Simultaneous Molecular Detection Method of HIV, HCV, and Syphilis from a Single Dried Blood Spot.
Jie Qiong MA ; Qing Qing XU ; Lin HE ; Xiao Xia HE ; Kai CHEN ; Yue Hua WANG ; Wen Ge XING ; Yan JIANG
Biomedical and Environmental Sciences 2021;34(4):257-264
		                        		
		                        			Objective:
		                        			The aim of the present study was to evaluate the performance of the simultaneous detection of HIV-1 RNA, HIV-1 DNA, and HCV RNA using one dried blood spot (DBS) as an alternative sample to plasma.
		                        		
		                        			Method:
		                        			A total of 571 paired DBS/plasma samples were collected from men who have sex with men (MSM) and injection drug users (IDUs), and serological and molecular assays were performed. Using plasma results as the reference standard, the performance of DBS tests for HIV-1 RNA, HIV-1 DNA, and HCV RNA was evaluated. Pearson's correlation coefficients and Bland-Altman analysis were performed to assess the correlation and concordance between DBS and plasma.
		                        		
		                        			Results:
		                        			Among paired plasma/DBS samples with detectable HIV-1 RNA and HCV RNA, five samples (5/32) were not detectable in DBS, while measurable HIV-1 RNA levels were present in plasma (1.44 to 3.99 log 
		                        		
		                        			Conclusion
		                        			The performance of the simultaneous detection of HIV-1 RNA, HIV-1 DNA, and HCV RNA using one DBS was acceptable. DBS, as an alternative sample to plasma, may be a viable option for the simultaneous detection of HIV-1 RNA, HIV-1 DNA, and HCV RNA in resource-limited settings or for individuals living in areas that are difficult to access.
		                        		
		                        		
		                        		
		                        			DNA, Viral/analysis*
		                        			;
		                        		
		                        			Diagnostic Tests, Routine/methods*
		                        			;
		                        		
		                        			Dried Blood Spot Testing/methods*
		                        			;
		                        		
		                        			HIV Infections/diagnosis*
		                        			;
		                        		
		                        			HIV-1/isolation & purification*
		                        			;
		                        		
		                        			Hepacivirus/isolation & purification*
		                        			;
		                        		
		                        			Hepatitis C/diagnosis*
		                        			;
		                        		
		                        			RNA, Viral/analysis*
		                        			;
		                        		
		                        			Sensitivity and Specificity
		                        			;
		                        		
		                        			Specimen Handling/methods*
		                        			;
		                        		
		                        			Syphilis/diagnosis*
		                        			;
		                        		
		                        			Treponema pallidum/isolation & purification*
		                        			
		                        		
		                        	
2.Pregnancy Outcomes in COVID-19: A Prospective Cohort Study in Singapore.
Citra Nz MATTAR ; Shirin KALIMUDDIN ; Sapna P SADARANGANI ; Shephali TAGORE ; Serene THAIN ; Koh Cheng THOON ; Eliane Y HONG ; Abhiram KANNEGANTI ; Chee Wai KU ; Grace Mf CHAN ; Kelvin Zx LEE ; Jeannie Jy YAP ; Shaun S TAN ; Benedict YAN ; Barnaby E YOUNG ; David C LYE ; Danielle E ANDERSON ; Liying YANG ; Lin Lin SU ; Jyoti SOMANI ; Lay Kok TAN ; Mahesh A CHOOLANI ; Jerry Ky CHAN
Annals of the Academy of Medicine, Singapore 2020;49(11):857-869
		                        		
		                        			INTRODUCTION:
		                        			Pregnant women are reported to be at increased risk of severe coronavirus disease 2019 (COVID-19) due to underlying immunosuppression during pregnancy. However, the clinical course of COVID-19 in pregnancy and risk of vertical and horizontal transmission remain relatively unknown. We aim to describe and evaluate outcomes in pregnant women with COVID-19 in Singapore.
		                        		
		                        			METHODS:
		                        			Prospective observational study of 16 pregnant patients admitted for COVID-19 to 4 tertiary hospitals in Singapore. Outcomes included severe disease, pregnancy loss, and vertical and horizontal transmission.
		                        		
		                        			RESULTS:
		                        			Of the 16 patients, 37.5%, 43.8% and 18.7% were infected in the first, second and third trimesters, respectively. Two gravidas aged ≥35 years (12.5%) developed severe pneumonia; one patient (body mass index 32.9kg/m2) required transfer to intensive care. The median duration of acute infection was 19 days; one patient remained reverse transcription polymerase chain reaction (RT-PCR) positive >11 weeks from diagnosis. There were no maternal mortalities. Five pregnancies produced term live-births while 2 spontaneous miscarriages occurred at 11 and 23 weeks. RT-PCR of breast milk and maternal and neonatal samples taken at birth were negative; placenta and cord histology showed non-specific inflammation; and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific immunoglobulins were elevated in paired maternal and umbilical cord blood (n=5).
		                        		
		                        			CONCLUSION
		                        			The majority of COVID-19 infected pregnant women had mild disease and only 2 women with risk factors (obesity, older age) had severe infection; this represents a slightly higher incidence than observed in age-matched non-pregnant women. Among the women who delivered, there was no definitive evidence of mother-to-child transmission via breast milk or placenta.
		                        		
		                        		
		                        		
		                        			Abortion, Spontaneous/epidemiology*
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			COVID-19/transmission*
		                        			;
		                        		
		                        			COVID-19 Nucleic Acid Testing
		                        			;
		                        		
		                        			COVID-19 Serological Testing
		                        			;
		                        		
		                        			Cohort Studies
		                        			;
		                        		
		                        			Disease Transmission, Infectious/statistics & numerical data*
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Fetal Blood/immunology*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Infectious Disease Transmission, Vertical/statistics & numerical data*
		                        			;
		                        		
		                        			Live Birth/epidemiology*
		                        			;
		                        		
		                        			Maternal Age
		                        			;
		                        		
		                        			Milk, Human/virology*
		                        			;
		                        		
		                        			Obesity, Maternal/epidemiology*
		                        			;
		                        		
		                        			Placenta/pathology*
		                        			;
		                        		
		                        			Pregnancy
		                        			;
		                        		
		                        			Pregnancy Complications, Infectious/physiopathology*
		                        			;
		                        		
		                        			Pregnancy Outcome/epidemiology*
		                        			;
		                        		
		                        			Pregnancy Trimester, First
		                        			;
		                        		
		                        			Pregnancy Trimester, Second
		                        			;
		                        		
		                        			Prospective Studies
		                        			;
		                        		
		                        			RNA, Viral/analysis*
		                        			;
		                        		
		                        			Risk Factors
		                        			;
		                        		
		                        			SARS-CoV-2
		                        			;
		                        		
		                        			Severity of Illness Index
		                        			;
		                        		
		                        			Singapore/epidemiology*
		                        			;
		                        		
		                        			Umbilical Cord/pathology*
		                        			;
		                        		
		                        			Young Adult
		                        			
		                        		
		                        	
3.Epidemiological characteristics of molecular transmission cluster among reported HIV/AIDS cases in Jiaxing city, Zhejiang province, 2017.
M Y LUO ; X H PAN ; Q FAN ; J F ZHANG ; R GE ; J JIANG ; W J CHEN
Chinese Journal of Epidemiology 2019;40(2):202-206
		                        		
		                        			
		                        			Objective: To understand the epidemiological characteristics of one large HIV molecular transmission cluster in Jiaxing city, Zhejiang province, 2017 in order to select those people under high-risk and providing basis for programs on prevention. Methods: During 2017, newly diagnosed HIV/AIDS cases in this city were recruited. Plasma samples were collected from subjects, followed by RNA extraction, RT-PCR and nest-PCR for pol gene amplification, before being sequenced and aligned. Mega 6.0 software was used to construct phylogenetic tree, and Cytoscape 3.6.0 software was used to identify HIV molecular transmission clusters. Cases within the large transmission clusters were investigated, using a field-epidemiology-questionnaire. Data related to socio-demographics and previous sexual behaviors were collected and EpiData 3.0 and SPSS 20.0 software were used. Results: In the large transmission cluster with subtype identified as CRF07_BC, in Jiaxing, 2017, 26 cases of the total 30 cases were investigated. A total of 80.8% (21/26) could be identified as newly infected within the last two years and 30.8%(8/26) could be identified as newly infected within the last one year, including 22 cases infected locally. Among several infected cases who were at age 45 years or older, they admitted that they had experienced unprotected sexual contacts in local city for long time and having had more than 10 disclosed sexual contacts within the last two years at the local venues. Conclusions: This molecular cluster had been formed and scaled up quickly in recent two years, it has played an important role in promoting and scaling up the HIV transmission. Three cases identificed as high risk played an importantrde role in scaling up this cluster.
		                        		
		                        		
		                        		
		                        			Amplified Fragment Length Polymorphism Analysis
		                        			;
		                        		
		                        			China/epidemiology*
		                        			;
		                        		
		                        			Genes, pol
		                        			;
		                        		
		                        			Genotype
		                        			;
		                        		
		                        			HIV Infections/transmission*
		                        			;
		                        		
		                        			HIV-1/isolation & purification*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Molecular Epidemiology
		                        			;
		                        		
		                        			Phylogeny
		                        			;
		                        		
		                        			Polymerase Chain Reaction
		                        			;
		                        		
		                        			RNA, Viral/blood*
		                        			;
		                        		
		                        			Sexual Behavior
		                        			;
		                        		
		                        			pol Gene Products, Human Immunodeficiency Virus
		                        			
		                        		
		                        	
4.Characteristic and dynamic of HIV-1 subtype distribution in men who have sex with men in Guangzhou, 2008-2015.
Z G HAN ; Y L ZHANG ; H WU ; W B CHENG ; C Y LIANG ; F ZHONG ; K GAO ; H F XU
Chinese Journal of Epidemiology 2018;39(1):67-71
		                        		
		                        			
		                        			Objective: To understand the characteristics and dynamic of HIV-1 subtype distribution in men who have sex with men (MSM) in Guangzhou between 2008 and 2015. Methods: HIV-1 RNAs were extracted from serum samples of the individuals newly diagnosed with HIV-1 infection among MSM living in Guangzhou between 2008 and 2015. The pol gene segments of HIV-1 genome from these RNA samples were amplified by nested reverse transcription polymerase chain reaction (nested-PCR) and were sequenced. Subsequently, the phylogenetic tree was reconstructed using pol sequences of samples and references together and the subtype of HIV-1 was determined. The distributions of HIV-1 subtypes detected in MSM with different demographic characteristics in different years were compared. Results: A total of 2 210 pol gene segments were successfully obtained from 2 473 serum samples of the MSM. The average age of 2 210 MSM was 30.19 years with standard deviation of 8.22 years, the unmarried MSM and those in Han ethnic group accounted for 73.39% and 90.81%, respectively. The proportion of subtype CRF07_BC (38.10%) was highest, followed by CRF01_AE (34.84%), CRF55_01B (14.62%), B (6.06%), URFs (3.58%), CRF59_01B (2.17%) and other subtypes (0.63%). The annual proportions of subtype B (P=0.000, 99%CI:0.000-0.000), CRF07_BC (χ(2)=14.965, P=0.036), CRF55_01B (χ(2)=18.161, P=0.011) and URFs (P=0.001, 99% CI: 0.000-0.001) were significantly different. The proportion of subtype B showed a gradual decrease from 14.08% to 4.33% (P=0.000, 99%CI: 0.000-0.000), while the proportion of URFs rapidly increased from 0% to 6.40% (P=0.000, 99% CI: 0.000-0.000). The rate of URFs was significantly higher in farmers and migrant workers than in other groups (P=0.017, 99%CI: 0.014- 0.020) and the rate of URFs was higher in individuals who had multi sexual partners (χ(2)=5.733, P=0.017). Conclusions: CRF07_BC and CRF01_AE were the predominant HIV-1 subtypes and multiple subtypes co-circulated among MSM in Guangzhou between 2008 and 2015. The recombinations of HIV-1 continue to occur in MSM. Strengthening behavioral intervention for farmers, migrant workers and individuals who have multi sexual partners has the important epidemiological significance against the emerging and circulating of the novel recombinant virus among MSM in Guangzhou.
		                        		
		                        		
		                        		
		                        			China/epidemiology*
		                        			;
		                        		
		                        			Genes, pol
		                        			;
		                        		
		                        			Genotype
		                        			;
		                        		
		                        			HIV Infections/virology*
		                        			;
		                        		
		                        			HIV Seropositivity/genetics*
		                        			;
		                        		
		                        			HIV-1/isolation & purification*
		                        			;
		                        		
		                        			Homosexuality, Male
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Phylogeny
		                        			;
		                        		
		                        			Polymerase Chain Reaction
		                        			;
		                        		
		                        			RNA, Viral/blood*
		                        			;
		                        		
		                        			Sexual Behavior
		                        			
		                        		
		                        	
5.Distribution of subtypes of pol gene in HIV-1 epidemic strains in Guangxi Zhuang Autonomous Region, 2010- 2012.
Hong WANG ; Bingyu LIANG ; Bo ZHOU ; Junjun JIANG ; Jiegang HUANG ; Rongfeng CHEN ; Fangning ZHAO ; Minlian WANG ; Jie LIU ; Wenwei LI ; Li YE ; Hao LIANG
Chinese Journal of Preventive Medicine 2016;50(1):79-84
OBJECTIVETo investigate the distribution and proportion of subtypes of pol gene in HIV-1 epidemic strains in Guangxi Autonomous Region.
METHODS152 HIV-1 patients were enrolled from 11 cities in Guangxi Autonomous Region from 2010 to 2012 by convenient sampling. Inclusion criterias were listed as the fdlowing: HIV-1 infection was confirmed by Western blot, HIV-1 viral load >1 000 copies/ml, > 18 year-old, and without any serious illnesses. 5 ml of peripheral blood samples were obtained from each patient. The viral RNA was isolated from plasma and used for amplification of full-length pol gene by nested RT-PCR. The amplified products were sequenced. After editing and modification, all sequences were characterized for preliminary subtyping by genotyping and confirmed with phylogenetic tree constructed by MEGA 5.03 software. The recombinant identification of 2 unknown recombinant strains was determined by RIP and jpHMM at GOBICS.
RESULTSAmong 152 patients, 137 full-length pol genes were successfully amplified and 127 HIV-1 subtypes were identified. The distribution and proportion of subtypes was summarized as the following 71 cases of CRF01_AE, accounting for 55.9% (71/127), 38 CRF08_BC, 29.9% (38/127), 13 CRF07_BC, 10.2% (13/127), and 3 B (B'), 2.4% (3/127), 2 unknown recombinant strains, 1.6% (2/127). In 11 cites of Guangxi Autonomous Region, subtype CRF01_AE was the dominant strain. Among heterosexual transmitted patients and drug abusers, the proportions of subtype CRF01_AE were 67.4% (58/86) and 34.1% (14/41), respectively. There was a significance different in the distribution of CRF01_AE in different routes of transmission (χ(2)=15.07, P<0.001). In age 21- 35, age 36- 60 and age>60 groups, the proportions of CRF01_AE was 43.6% (17/39), 57.6% (38/66), 77.3% (17/22), and CRF08_BC was 43.6% (17/39), 28.8% (19/66), 9.1% (2/22), respectively, the difference in proportions was significant(χ(2)=8.48, P= 0.014). The patterns of two unknown recombinant strains were found to be CRF01_AE/B (B') and CRF01_AE/C/B(B'), respectively.
CONCLUSIONCRF01_AE was the dominant HIV-1 subtype in Guangxi Autonomous Region from 2010 to 2012, with heterosexual transmission as its main spreading route. The two unknown recombinant strains in Guangxi Autonomous Region were reconstructed by subtype CRF01_AE and CRF_BC.
Blotting, Western ; China ; epidemiology ; Cities ; Drug Users ; Genes, pol ; Genotype ; HIV Infections ; epidemiology ; transmission ; virology ; HIV-1 ; genetics ; Humans ; Phylogeny ; Polymerase Chain Reaction ; RNA, Viral ; blood ; pol Gene Products, Human Immunodeficiency Virus ; genetics
6.First Imported Case of Zika Virus Infection into Korea.
Hee Chang JANG ; Wan Beom PARK ; Uh Jin KIM ; June Young CHUN ; Su Jin CHOI ; Pyoeng Gyun CHOE ; Sook In JUNG ; Youngmee JEE ; Nam Joong KIM ; Eun Hwa CHOI ; Myoung Don OH
Journal of Korean Medical Science 2016;31(7):1173-1177
		                        		
		                        			
		                        			Since Zika virus has been spreading rapidly in the Americas from 2015, the outbreak of Zika virus infection becomes a global health emergency because it can cause neurological complications and adverse fetal outcome including microcephaly. Here, we report clinical manifestations and virus isolation findings from a case of Zika virus infection imported from Brazil. The patient, 43-year-old Korean man, developed fever, myalgia, eyeball pain, and maculopapular rash, but not neurological manifestations. Zika virus was isolated from his semen, and reverse-transcriptase PCR was positive for the virus in the blood, urine, and saliva on the 7th day of the illness but was negative on the 21st day. He recovered spontaneously without any neurological complications. He is the first case of Zika virus infection in Korea imported from Brazil.
		                        		
		                        		
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Brazil
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Microscopy, Electron, Transmission
		                        			;
		                        		
		                        			RNA, Viral/analysis/blood/urine
		                        			;
		                        		
		                        			Republic of Korea
		                        			;
		                        		
		                        			Reverse Transcriptase Polymerase Chain Reaction
		                        			;
		                        		
		                        			Saliva/virology
		                        			;
		                        		
		                        			Semen/virology
		                        			;
		                        		
		                        			Travel
		                        			;
		                        		
		                        			Zika Virus/genetics/*isolation & purification
		                        			;
		                        		
		                        			Zika Virus Infection/*diagnosis/virology
		                        			
		                        		
		                        	
7.A Case Report of a Middle East Respiratory Syndrome Survivor with Kidney Biopsy Results.
Ran Hui CHA ; Seung Hee YANG ; Kyung Chul MOON ; Joon Sung JOH ; Ji Yeon LEE ; Hyoung Shik SHIN ; Dong Ki KIM ; Yon Su KIM
Journal of Korean Medical Science 2016;31(4):635-640
		                        		
		                        			
		                        			A 68-year old man diagnosed with Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) presented with multiple pneumonic infiltrations on his chest X-ray, and the patient was placed on a mechanical ventilator because of progressive respiratory failure. Urinary protein excretion steadily increased for a microalbumin to creatinine ratio of 538.4 mg/g Cr and a protein to creatinine ratio of 3,025.8 mg/g Cr. The isotope dilution mass spectrometry traceable serum creatinine level increased to 3.0 mg/dL. We performed a kidney biopsy 8 weeks after the onset of symptoms. Acute tubular necrosis was the main finding, and proteinaceous cast formation and acute tubulointerstitial nephritis were found. There were no electron dense deposits observed with electron microscopy. We could not verify the virus itself by in situ hybridization and confocal microscopy (MERS-CoV co-stained with dipeptidyl peptidase 4). The viremic status, urinary virus excretion, and timely kidney biopsy results should be investigated with thorough precautions to reveal the direct effects of MERS-CoV with respect to renal complications.
		                        		
		                        		
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Biopsy
		                        			;
		                        		
		                        			Coronavirus Infections/*diagnosis/virology
		                        			;
		                        		
		                        			Creatinine/blood/urine
		                        			;
		                        		
		                        			Dipeptidyl Peptidase 4/metabolism
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			In Situ Hybridization, Fluorescence
		                        			;
		                        		
		                        			Kidney/metabolism/*pathology
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Microscopy, Confocal
		                        			;
		                        		
		                        			Microscopy, Electron
		                        			;
		                        		
		                        			Middle East Respiratory Syndrome Coronavirus/*genetics/isolation & purification
		                        			;
		                        		
		                        			RNA, Viral/genetics/metabolism
		                        			;
		                        		
		                        			Reverse Transcriptase Polymerase Chain Reaction
		                        			;
		                        		
		                        			Serum Albumin/analysis
		                        			
		                        		
		                        	
8.Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.
Hee Chul NAM ; Hae Lim LEE ; Hyun YANG ; Myeong Jun SONG
Clinical and Molecular Hepatology 2016;22(2):259-266
		                        		
		                        			
		                        			BACKGROUND/AIMS: The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV). We evaluated the efficacy and safety of DCV and ASV for HCV in real-life practice. METHODS: Patients were treated with 60 mg of DCV once daily plus 200 mg of ASV twice daily for 24 weeks, and followed for 12 weeks. The primary endpoint was a sustained virological response at 12 weeks after treatment (SVR12) and safety. RESULTS: This retrospective study included eight patients with chronic HCV genotype 1b infection. All of the enrolled patients were diagnosed with liver cirrhosis, and their mean age was 65.75 years. One patient was a nonresponder and two patients relapsed with previous pegylated interferon (PegIFN) and ribavirin (RBV) treatment. None of the patient showed NS5A mutation. An SVR12 was achieved in 88% of cases by the DCV and ASV combination therapy. The serum transaminase level and the aspartate-aminotransferase-to-platelet ratio were improved after the treatment. DCV and ASV were well tolerated in most of the patients, with treatment discontinuation due to adverse events (elevated liver enzyme and decompensation) occurring in two patients. CONCLUSIONS: In this study, combination of DCV and ASV treatment achieved a high sustained virological response with few adverse events even in those with cirrhosis, advanced age, and nonresponse/relapse to previous interferon-based therapy. Close monitoring of safety issues may be necessary when treating chronic HCV patients receiving DCV and ASV, especially in older patient and those with cirrhosis.
		                        		
		                        		
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Alanine Transaminase/blood
		                        			;
		                        		
		                        			Antiviral Agents/*therapeutic use
		                        			;
		                        		
		                        			Aspartate Aminotransferases/blood
		                        			;
		                        		
		                        			Drug Administration Schedule
		                        			;
		                        		
		                        			Drug Resistance, Viral
		                        			;
		                        		
		                        			Drug Therapy, Combination
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Genotype
		                        			;
		                        		
		                        			Hepacivirus/*genetics/isolation & purification
		                        			;
		                        		
		                        			Hepatitis C, Chronic/complications/*drug therapy/virology
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Imidazoles/*therapeutic use
		                        			;
		                        		
		                        			Isoquinolines/*therapeutic use
		                        			;
		                        		
		                        			Liver/diagnostic imaging
		                        			;
		                        		
		                        			Liver Cirrhosis/complications
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			RNA, Viral/blood
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Sulfonamides/*therapeutic use
		                        			;
		                        		
		                        			Treatment Outcome
		                        			
		                        		
		                        	
9.Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection.
Jong Man KIM ; Kwang Woong LEE ; Gi Won SONG ; Bo Hyun JUNG ; Hae Won LEE ; Nam Joon YI ; ChoonHyuck David KWON ; Shin HWANG ; Kyung Suk SUH ; Jae Won JOH ; Suk Koo LEE ; Sung Gyu LEE
Clinical and Molecular Hepatology 2016;22(3):366-371
		                        		
		                        			
		                        			BACKGROUND/AIMS: The relationship between patient survival and biopsy-proven acute rejection (BPAR) in liver transplant recipients with hepatitis C remains unclear. The aims of this study were to compare the characteristics of patients with and without BPAR and to identify risk factors for BPAR. METHODS: We retrospectively reviewed the records of 169 HCV-RNA-positive patients who underwent LT at three centers. RESULTS: BPAR occurred in 39 (23.1%) of the HCV-RNA-positive recipients after LT. The 1-, 3-, and 5-year survival rates were 92.1%, 90.3%, and 88.5%, respectively, in patients without BPAR, and 75.7%, 63.4%, and 58.9% in patients with BPAR (P<0.001). Multivariate analyses showed that BPAR was associated with the non-use of basiliximab and tacrolimus and the use of cyclosporin in LT recipients with HCV RNA-positive. CONCLUSION: The results of the present study suggest that the immunosuppression status of HCV-RNA-positive LT recipients should be carefully determined in order to prevent BPAR and to improve patient survival.
		                        		
		                        		
		                        		
		                        			Antibodies, Monoclonal/therapeutic use
		                        			;
		                        		
		                        			Biopsy
		                        			;
		                        		
		                        			Cyclosporine/therapeutic use
		                        			;
		                        		
		                        			Drug Therapy, Combination
		                        			;
		                        		
		                        			Genotype
		                        			;
		                        		
		                        			Graft Rejection/mortality/*prevention & control
		                        			;
		                        		
		                        			Hepacivirus/genetics/isolation & purification
		                        			;
		                        		
		                        			Hepatitis C/drug therapy/*virology
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Immunosuppressive Agents/*therapeutic use
		                        			;
		                        		
		                        			*Liver Transplantation/adverse effects
		                        			;
		                        		
		                        			Polymerase Chain Reaction
		                        			;
		                        		
		                        			RNA, Viral/blood
		                        			;
		                        		
		                        			Recombinant Fusion Proteins/therapeutic use
		                        			;
		                        		
		                        			Recurrence
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Survival Rate
		                        			;
		                        		
		                        			Tacrolimus/therapeutic use
		                        			
		                        		
		                        	
10.Residual Risk of Transfusion-Transmitted Infection with Hepatitis C Virus since the Introduction of Nucleic Acid Testing in Korea.
Deokja OH ; Gyeryung CHOI ; Hyukki MIN ; Jaewon KANG
Korean Journal of Blood Transfusion 2015;26(2):193-203
		                        		
		                        			
		                        			BACKGROUND: In 2005, the Korean Red cross introduced mini-pool nucleic acid testing (NAT) for human immunodeficiency virus (HIV) and hepatitis C virus (HCV), which upgraded to individual donation (ID) NAT including HBV in 2012. In this study, we analyzed the trend of HCV infection among blood donors after introduction of NAT by estimating the residual risk (RR) of transfusion transmitted infection (TTI) of HCV. METHODS: Donation data from 2003 to 2014 were analyzed using the Blood Information Management System (BIMS). Each donation was tested for antibodies and viral RNA for HCV. Prevalence and incidence rate (IR) among repeat donors were determined. RR was determined using the incidence rate/window period model. RESULTS: During the 12-year period, a total of 29,058,436 donations were screened with 34 HCV NAT yield donations. Calculated RR per million donations for HCV was significantly reduced from 13.41 in the pre-NAT period (2003~2004) to 0.52 in the post NAT period (2006~2007) (P<0.001). Most recently (2013~2014), RR for HCV with TTI was estimated by 0.16 per million donations (1:6,289,308). CONCLUSION: RR of TTI with HCV was remarkably decreased since introduction of NAT. However, the prevalence and IR of HCV RNA among first time donors was still high and yield cases were more frequent among repeat donors. Therefore, establishment of a sensitive and accurate screening system and measures for maintaining healthy donors should be considered in order to ensure blood safety.
		                        		
		                        		
		                        		
		                        			Antibodies
		                        			;
		                        		
		                        			Blood Donors
		                        			;
		                        		
		                        			Blood Safety
		                        			;
		                        		
		                        			Hepacivirus*
		                        			;
		                        		
		                        			Hepatitis C*
		                        			;
		                        		
		                        			Hepatitis*
		                        			;
		                        		
		                        			HIV
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Incidence
		                        			;
		                        		
		                        			Information Management
		                        			;
		                        		
		                        			Korea*
		                        			;
		                        		
		                        			Mass Screening
		                        			;
		                        		
		                        			Prevalence
		                        			;
		                        		
		                        			Red Cross
		                        			;
		                        		
		                        			RNA
		                        			;
		                        		
		                        			RNA, Viral
		                        			;
		                        		
		                        			Tissue Donors
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail